New Biopharma Portfolio
For Single-Use Applications
Solvay SA, Brussels, Belgium, has unveiled a broad portfolio of medical-grade specialty polymers for single-use biopharmaceutical manufacturing applications. Encompassing select grades from five of its most recognized product families, the new portfolio aims to support the industry’s shift toward single-use peripherals, filtration, bioreactors and containment. According to Solvay, it will help biopharmaceutical manufacturers achieve greater flexibility, faster product development, reduced capital costs and increased speed to market.
The five product families from which Solvay assembled its new biopharmaceutical manufacturing portfolio include:
- Radel polyphenylsulfone (PPSU)
- Udel polysulfone (PSU)
- AvaSpire polyaryletherketone (PAEK)
- KetaSpire polyetheretherketone (PEEK)
- Ixef polyarylamide (PARA)
In qualifying materials for single-use applications, Solvay evaluated the effect of gamma irradiation up to 50 kGy on each polymer to ensure it would retain excellent mechanical performance and other application-critical properties. Results confirmed each material’s compatibility with gamma irradiation, the preferred sterilization method for single-use systems.
All materials are certified under United States Pharmacopeia (USP) Class VI test standards – before and after gamma irradiation – to ensure they meet stringent industry requirements. Solvay is also following industry guidelines to evaluate leachables and extractables for its biopharma portfolio.
Patents encourage innovation: Stay on the ball with the latest innovations in the plastics industry in our patents section.
Would you like to subscribe to our Newsletters on plastics technology and profit from the latest information?
You know the trade name but want to know the material manufacturer, type of polymer and delivery form? Search here!